Perrigo (NYSE:PRGO) Issues FY 2025 Earnings Guidance

Perrigo (NYSE:PRGO - Get Free Report) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 2.900-3.100 for the period, compared to the consensus earnings per share estimate of 3.020. The company issued revenue guidance of $4.4 billion-$4.5 billion, compared to the consensus revenue estimate of $4.6 billion. Perrigo also updated its FY25 guidance to $2.90-3.10 EPS.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Piper Sandler cut shares of Perrigo from an "overweight" rating to a "neutral" rating and lowered their target price for the stock from $34.00 to $27.00 in a research note on Monday, January 6th. Argus cut shares of Perrigo from a "buy" rating to a "hold" rating in a research note on Tuesday, January 14th. Finally, StockNews.com downgraded shares of Perrigo from a "buy" rating to a "hold" rating in a report on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, Perrigo presently has an average rating of "Hold" and an average target price of $33.00.

Perrigo Trading Up 1.3 %

Shares of PRGO traded up $0.37 during midday trading on Tuesday, reaching $29.37. The company had a trading volume of 3,037,248 shares, compared to its average volume of 1,490,965. The firm has a 50 day simple moving average of $25.00 and a 200-day simple moving average of $26.20. The company has a quick ratio of 1.77, a current ratio of 2.56 and a debt-to-equity ratio of 0.94. The stock has a market cap of $4.01 billion, a PE ratio of -25.10 and a beta of 0.54. Perrigo has a 1-year low of $23.14 and a 1-year high of $33.46.

Remove Ads

Perrigo (NYSE:PRGO - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.01. The firm had revenue of $1.14 billion during the quarter, compared to analysts' expectations of $1.20 billion. Perrigo had a negative net margin of 3.64% and a positive return on equity of 7.38%. Research analysts forecast that Perrigo will post 2.56 EPS for the current fiscal year.

Perrigo Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 25th. Investors of record on Friday, March 7th will be issued a $0.29 dividend. The ex-dividend date of this dividend is Friday, March 7th. This is a boost from Perrigo's previous quarterly dividend of $0.28. This represents a $1.16 dividend on an annualized basis and a yield of 3.95%. Perrigo's dividend payout ratio is currently -92.80%.

Insiders Place Their Bets

In other Perrigo news, Director Jeffrey B. Kindler sold 17,598 shares of the stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $28.27, for a total transaction of $497,495.46. Following the completion of the transaction, the director now owns 5,409 shares of the company's stock, valued at $152,912.43. This trade represents a 76.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.70% of the stock is owned by insiders.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.